No Data
No Data
United States Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring BD, Roche, Medtronic, Insulet, Abbott, Dexcom, Tandem Diabetes Care, Ypsomed Novo Nordisk, Eli Lilly - ResearchAndMarkets.com
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Unlock the Full List